The companies will work together to identify and optimize certain microbiome repertoire associated with the response to Aramchol, Galmed's investigational NASH treatment drug. They will also develop a standalone microbiome-based treatment for NASH and fibrosis as well as to identify specific microbial biomarkers for Aramchol.

The collaboration will utilize MyBiotics' SuperDonor and MyLiveIn solutions to identify and optimize bacteria to reconstitute gut flora in patients with NASH, helping to improve the clinical efficacy and response rate of Aramchol. The MyBiotics microbiome therapeutic technology can increase bacterial diversity, which can be leveraged for product candidates and to produce bacteria more resistant to gastrointestinal conditions.

Genome & Company doses patients in immuno-oncology microbiome therapeutic trial
Genome & Company has initiated clinical testing of GEN-001, an anti-cancer microbiome therapeutic, six months after its investigational new drug approval.

Could heparin-based therapies be a viable treatment for COVID-19?
Researchers have identified a novel approach to treating SARS-CoV-2 infection, spurred by a new understanding of viral attachment involving a heparan...

Microbes shape antibodies prior to infection
Genetic analysis of antibodies reveals how microbes in the intestines impact overall B-cell populations and humoral responses to pathogens. The research...

Enterome begins trial for microbiome-based immunotherapy
Clinical-stage biopharmaceutical company Enterome has begun its first clinical trial for E02401, a microbiome-based cancer immunotherapy candidate.